Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04NXL
|
|||
Former ID |
DCL001197
|
|||
Drug Name |
Indibulin
|
|||
Synonyms |
Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Advanced sarcoma [ICD-11: 2A60-2C35; ICD-10: C96.4] | Phase 2 | [1] | |
Company |
ZioPharm
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H16ClN3O2
|
|||
Canonical SMILES |
C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4
|
|||
InChI |
1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)
|
|||
InChIKey |
SOLIIYNRSAWTSQ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 204205-90-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
5062799, 7636306, 7736964, 8151871, 14805166, 26758534, 29216109, 29222082, 49983107, 53657486, 53800806, 89589210, 103113279, 103229280, 104302033, 117537797, 118034213, 118276877, 121927041, 125487494, 126671561, 129265815, 131902607, 135252144, 135626734, 135698501, 137249120, 139036173, 143402550, 163123192, 163688303, 163694559, 164043539, 170270272, 172869441, 174007308, 181907953, 198979077, 204371018, 208265016, 223603494, 223663616, 229206720, 241051133, 249804737, 250003153, 251960656, 252157489, 252215589, 252434733
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin (TUB) | Target Info | Stablizer | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | 2011 Pipeline of ZioPharm. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.